Coeptis Therapeutics (NASDAQ:ZSQR) Trading 7.2% Higher – Still a Buy?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s share price shot up 7.2% on Tuesday . The stock traded as high as $10.85 and last traded at $10.81. 73,918 shares changed hands during mid-day trading, a decline of 27% from the average session volume of 101,058 shares. The stock had previously closed at $10.08.

Coeptis Therapeutics Price Performance

The firm has a fifty day moving average of $11.91 and a two-hundred day moving average of $13.10. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $547.73 million, a PE ratio of -4.23 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Trading of Coeptis Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of Coeptis Therapeutics during the 4th quarter valued at about $259,000. State Street Corp lifted its stake in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the period. Steward Partners Investment Advisory LLC boosted its position in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares in the last quarter. Finally, Yorkville Advisors Global LP purchased a new stake in Coeptis Therapeutics in the third quarter worth $140,000. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.